Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 1
2012 3
2013 2
2014 5
2015 4
2016 9
2017 12
2018 18
2019 58
2020 42
2021 46
2022 53
2023 54
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Results by year

Filters applied: . Clear all
Page 1
Omadacycline.
[No authors listed] [No authors listed] 2020 Sep 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Sep 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30601611 Free Books & Documents. Review.
No information is available on the use of omadacycline during breastfeeding. It is unknown how much omadacycline is excreted into breastmilk, but the drug is only about 35% absorbed orally under optimal circumstances, and is probably less from milk because of its ca …
No information is available on the use of omadacycline during breastfeeding. It is unknown how much omadacycline is excreted i …
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP 3rd, Karlowsky JA. Zhanel GG, et al. Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4. Drugs. 2020. PMID: 31970713 Review.
Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. ...Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profil …
Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. ...Mild, transient gastrointestinal events are …
Omadacycline.
[No authors listed] [No authors listed] 2020 Jan 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Jan 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643226 Free Books & Documents. Review.
Omadacycline is an oral, tetracycline-like antibiotic used to treat moderate-to-severe infections including community-acquired pneumonia and acute bacterial skin and skin structure infections caused by susceptible organisms. Oral omadacycline use has been associated …
Omadacycline is an oral, tetracycline-like antibiotic used to treat moderate-to-severe infections including community-acquired pneumo …
Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Stets R, et al. N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201. N Engl J Med. 2019. PMID: 30726692 Clinical Trial.
Twelve deaths (8 in the omadacycline group and 4 in the moxifloxacin group) occurred during the trial. CONCLUSIONS: Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults. ...
Twelve deaths (8 in the omadacycline group and 4 in the moxifloxacin group) occurred during the trial. CONCLUSIONS: Omadacycline …
Omadacycline.
Baker DE. Baker DE. Hosp Pharm. 2019 Apr;54(2):80-87. doi: 10.1177/0018578718823730. Epub 2019 Jan 22. Hosp Pharm. 2019. PMID: 30923399 Free PMC article. Review.
Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA, Sucher AJ, Chahine EB, Shihadeh KC. Dougherty JA, et al. Ann Pharmacother. 2019 May;53(5):486-500. doi: 10.1177/1060028018818094. Epub 2018 Dec 7. Ann Pharmacother. 2019. PMID: 30917674 Review.
Omadacycline provides clinicians with an additional parenteral and oral option for the treatment of adults with ABSSSI and CABP. CONCLUSION: Omadacycline is an alternative treatment option for ABSSSI and CABP....
Omadacycline provides clinicians with an additional parenteral and oral option for the treatment of adults with ABSSSI and CABP. CONC …
Omadacycline: a novel aminomethylcycline.
Burgos RM, Rodvold KA. Burgos RM, et al. Infect Drug Resist. 2019 Jul 2;12:1895-1915. doi: 10.2147/IDR.S171352. eCollection 2019. Infect Drug Resist. 2019. PMID: 31308710 Free PMC article. Review.
However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the glycylcylcines. Omadacycline, a new and improved tetracycline, has demonstrated a broad spectrum of in v …
However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral b …
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.
Rodvold KA, Burgos RM, Tan X, Pai MP. Rodvold KA, et al. Clin Pharmacokinet. 2020 Apr;59(4):409-425. doi: 10.1007/s40262-019-00843-4. Clin Pharmacokinet. 2020. PMID: 31773505 Review.
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). ...Omadacycline has a large volume of distribution (190 L) and low plasma protein binding (21.3%) that was concentration independent. ...
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). ...Omadacycline has a large volume of distribution (190 …
Omadacycline in treating community-based infections: a review and expert perspective.
Sakoulas G, Nowak M, Geriak M. Sakoulas G, et al. Expert Rev Anti Infect Ther. 2023 Mar;21(3):255-265. doi: 10.1080/14787210.2023.2174100. Epub 2023 Feb 6. Expert Rev Anti Infect Ther. 2023. PMID: 36718489 Review.
INTRODUCTION: Omadacycline is approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and soft tissue infection (ABSSSI). The integration of newer agents into clinical use involves understanding the nuances of clinical decision- …
INTRODUCTION: Omadacycline is approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin an …
Omadacycline: First Global Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2018 Dec;78(18):1931-1937. doi: 10.1007/s40265-018-1015-2. Drugs. 2018. PMID: 30471003 Review.
Paratek Pharmaceuticals are developing omadacycline (NUZYRA), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections. ...This article summarizes the milestones in the development of omadacycline leading to th …
Paratek Pharmaceuticals are developing omadacycline (NUZYRA), a first-in-class orally active aminomethylcycline antibacterial, as a t …
302 results